Hiperkalsemi
Synopsis
Hypercalcemia is a common electrolyte disorder encountered in emergency departments, defined as a serum total calcium level above 10.5 mg/dL or an ionized calcium level above 2.7 mEq/L. While its most common causes are malignancies and primary hyperparathyroidism primarily driven by solitary parathyroid adenomas, endocrine disorders, granulomatous diseases, vitamins A and D, lithium, thiazide diuretics, dehydration, and immobilization can also lead to hypercalcemia. Ionized calcium is the active form in blood, and its increase negatively affects cellular conduction, cardiac automaticity, and renal concentrating ability. Patients may present with non-specific complaints such as nausea, vomiting, fatigue, anorexia, and polyuria, while severe cases may exhibit neuropsychiatric disorders, dysrhythmias, QT shortening and ST elevation on ECG, and renal failure. For diagnosis, serum calcium is classified as mild (10.5–11.9 mg/dL), moderate (12–13.9 mg/dL), and severe (≥14 mg/dL). In cases of albumin abnormalities, calcium must be corrected by 0.8 mg/dL for every 1 g/dL change in albumin. The PTH level is the key parameter in differential diagnosis; high PTH indicates primary hyperparathyroidism, whereas low PTH points to malignancy. The mainstay of treatment is rapid saline infusion. Furosemide may be added following adequate hydration. In severe cases, bisphosphonates such as zoledronic acid, calcitonin, corticosteroids, and denosumab are used. For patients with anuria, severe renal failure, or refractory hypercalcemic crisis, emergency hemodialysis or emergency parathyroidectomy is required.
References
Goltzman D.(2000) Approach to Hypercalcemia. In: De Groot LJ, Chrousos G(Ed.); Dungan K, et al., editors. Approach to Hypercalcemia. South Dartmouth (MA): MDText.com.
Petrina R, Marino R. (2016). Fluids and Electrolytes. In: Tintinalli JE, Ma
OJ, Yealy DM, Meckler GD, Stapczynski JS, Cline DM(Ed.) editors. Tintinalli’s Emergency Medicine: A Comprehensive Study Guide (p.109-110). Eighth Edition. New York: McGraw-Hill.
Stewart AF. Hypercalcemia associated with cancer. N Engl J Med. 2005;352:373-382
Lumachi F, Brunello A, Roma A, Basso U. Medical treatment of malignancy-associated hypercalcemia. Curr Med Chem. 2008;15:415-421.
Pfennig CL, Slovis CM. (2014). Electrolyte Disorders. John A. Marx(Ed.), Rosen’s Emergency Medicine: Concepts and Clinical Practice 8th(16451646).Philadelphia: Elsevier Saunder.
SB LeGrand, D Leskuski, I Zama: Narrative review: Furosemide for hypercalcemia: An unproven yet common practice Ann Intern Med 149:259–263,2008.
Marcocci C. Cetani F. Primary hyperparathyroidism. N Engl J Med. 2011;365:2389–97.
Walsh J. Gittoes N. Selby P. Emergency management of acute hypercalcaemia in adult patients. Endocr Connect. 2016;5:G9–G11.
Vassilopoulou-Sellin R, Newman BM, Taylor SH, Guinee VF:Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 71:1309-1312, 1993
Sleeboom HP, Bijvoet OLM, Van Oosterom AT: Comparison of intravenous (3-amino-1-hydroxypropylidene)-1-1-bisphosphonate and volume repletion in tumor-induced hypercalcemia. Lancet 2:239-243, 1983
Major P, Lortholary A, Hon J : Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19: 558–567, 2001
Bilezikian JP: Management of acute hypercalcemia. N Engl J Med 326: 1196–1203, 1992
Strewler GJ(1997): Humoral manifestations of malignancy. In: Greenspan FS, Strewler GJ (Ed.) Basic & ClinicalEndocrinology(pp. 741752) Stamford, CT, Appleton Lange.
Body JJ : A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12: 1221-1228, 2006
Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677–692.
Stewart AF, Horst R, Deftos LJ. Biochemical evaluation of patients with cancer-associated hypercalcemia: Evidence for humoral and non-humoral groups. N. Engl. J. Med. 1980;303:1377–1383.
Walser M. Ion association: VI. Interactions between calcium, magnesium, inorganic phosphate, citrate, and protein in normal human plasma. J. Clin. Invest. 1961;40:723–730